Analyzing urinary hippuric acid as a metabolic health biomarker through a supramolecular architecture

The prevalence of metabolic disorders has been found to increase concomitantly with alternations in habitual diet and lifestyle, indicating the importance of metabolic health monitoring for early warning of high-risk status and suggesting effective intervention strategies. Hippuric acid (HA), as one of the most abundant metabolites from the gut microbiota, holds potential as a regulator of metabolic health. Accordingly, it is imperative to establish an efficient, sensitive, and affordable method for large-scale population monitoring, revealing the association between HA level and metabolic disorders. Upon systematic screening of macrocycle•dye reporter pair, a supramolecular architecture (guanidinomethyl-modified calix[5]arene, GMC5A) was employed to sense urinary HA by employing fluorescein (Fl), whose complexation behavior was demonstrated by theoretical calculations, accomplishing quantification of HA in urine from 249 volunteers in the range of 0.10 mM and 10.93 mM. Excitedly, by restricted cubic spline, urinary HA concentration was found to have a significantly negative correlation with the risk of metabolic disorders when it exceeded 0.76 mM, suggesting the importance of dietary habits, especially the consumption of fruits, coffee, and tea, which was unveiled from a simple questionnaire survey. In this study, we accomplished a high throughput and sensitive detection of urinary HA based on supramolecular sensing with the GMC5A•Fl reporter pair, which sheds light on the rapid quantification of urinary HA as an indicator of metabolic health status and early intervention by balancing the daily diet.

Molecularly imprinted electrochemical sensor based on CoNi-MOF/RGO nanocomposites for sensitive detection of the hippuric acid

Toluene, a volatile organic compound, may have adverse effects on the nervous and digestive system when inhaled over an extended period. The assessment of environmental toluene exposure can be effectively conducted by detecting hippuric acid (HA), a toluene metabolite. In this investigation, a molecularly imprinted electrochemical sensor was developed for HA detection, utilizing the synergistic effects of reduced graphene oxide (RGO) and a bimetallic organic skeleton known as CoNi-MOF. Initially, graphene oxide (GO) was synthesized using a modified Hummers' method, and RGO with better conductivity was achieved through reduction with ascorbic acid (AA). Subsequently, CoNi-MOF was introduced to enhance the material's electron transport capabilities further. The molecularly imprinted membrane was then prepared via electropolymerization to enable selective HA recognition. Under optimal conditions, the synthesized sensor exhibited accurate HA detection within a concentration range of 2-800 nM, with a detection limit of 0.97 nM. The sensor's selectivity was assessed using a selectivity coefficient, yielding an imprinting factor of 6.53. The method was successfully applied to the quantification of HA in urine, demonstrating a favorable recovery rate of 93.4%-103.9%. In conclusion, this study presents a practical platform for the detection of human metabolite detection.

A Simple Interfacial Platform for Homogeneous Electrochemical Immunoassays Using a Poly(Vinylimidazole)-Modified Electrode

In this study, a homogeneous method featuring simple, one-step detection was developed to analyze hippuric acid (HA), a major metabolite of toluene. High sensitivity was achieved with the facile immobilization of poly(vinylimidazole) (PVI) on an indium tin oxide (ITO) electrode. Using a previously developed approach, pentacyanoferrate was coordinated with pyridyl-N ligands, and the redox-active Fe(II/III) centers were bound to Ni(II) ions on the electrode via electrostatic cyanide bridges. The detection was accomplished by the competitive binding of free HA and pentacyanoferrate-(4-aminomethylpyridine-hippuric acid) (Fe-HA, the electron transfer mediator) to the HA antibody on the Ni(II) ions-modified PVI-ITO (Ni-PVI-ITO) electrode. The electrical and physicochemical characterization of the electrode was carried out by cyclic voltammetry, differential pulse voltammetry, field emission scanning electron microscopy, and X-ray photoelectron spectroscopy. At low mediator concentrations, the electrical signals were proportional to the HA concentration between 0.1 µg/mL and 1.0 mg/mL. The same method may be extended to other small organic molecules.

Lab on a chip for in situ diagnosis: From blood to point of care

As the point of care diagnosis devices are becoming ever more popular, this paper suggest a miniaturized testing device from a drop of blood to diagnosis of disease for the global healthcare. The minimal requirements for the POC blood-testing device are blood microsampling, blood separation, immunoassay, and detection and communication of the signals. The microsampling of the blood can be achieved by specialized needle, which can be connected to the microchip or analytical devices. The sampled blood is then separated using either a filter (weir or pillar type), or by the phenomena unique to microfluidic system. The separated blood should then go through sandwich, homogeneous non-competitive, or competitive immunoassay, which can effectively diagnose diverse diseases. Lastly, the device should detect and translate the immune-signals to readable, and clinically significant signals. The development of such device will play a great role for improving healthcare technology.

Microfluidic chips for immunoassays

The use of microfluidic chips for immunoassays has been extensively explored in recent years. The combination of immunoassays and microfluidics affords a promising platform for multiple, sensitive, and automatic point-of-care (POC) diagnostics. In this review, we focus on the description of recent achievements in microfluidic chips for immunoassays categorized by their detection method. Following a brief introduction to the basic principles of each detection method, we examine current microfluidic immunosensor detection systems in detail. We also highlight interesting strategies for sensitive immunosensing configurations, multiplexed analysis, and POC diagnostics in microfluidic immunosensors.

Urine analysis in microfluidic devices

Microfluidics has attracted considerable attention since its early development in the 1980s and has experienced rapid growth in the past three decades due to advantages associated with miniaturization, integration and automation. Urine analysis is a common, fast and inexpensive clinical diagnostic tool in health care. In this article, we will be reviewing recent works starting from 2005 to the present for urine analysis using microfluidic devices or systems and to provide in-depth commentary about these techniques. Moreover, commercial strips that are often treated as chips and their readers for urine analysis will also be briefly discussed. We start with an introduction to the physiological significance of various components or measurement standards in urine analysis, followed by a brief introduction to enabling microfluidic technologies. Then, microfluidic devices or systems for sample pretreatments and for sensing urinary macromolecules, micromolecules, as well as multiplexed analysis are reviewed, in this sequence. Moreover, a microfluidic chip for urinary proteome profiling is also discussed, followed by a section discussing commercial products. Finally, the authors' perspectives on microfluidic-based urine analysis are provided. These advancements in microfluidic techniques for urine analysis may improve current routine clinical practices, particularly for point-of-care (POC) applications.

Integrated electrokinetic magnetic bead-based electrochemical immunoassay on microfluidic chips for reliable control of permitted levels of zearalenone in infant foods

Microfluidic technology has now become a novel sensing platform where different analytical steps, biological recognition materials and suitable transducers can be cleverly integrated yielding a new sensor generation. A novel "lab-on-a-chip" strategy integrating an electrokinetic magnetic bead-based electrochemical immunoassay on a microfluidic chip for reliable control of permitted levels of zearalenone in infant foods is proposed. The strategy implies the creative use of the simple channel layout of the double-T microchip to perform sequentially the immunointeraction and enzymatic reaction by applying a program of electric fields suitably connected to the reservoirs for driving the fluidics at different chambers in order to perform the different reactions. Both zones are used with the aid of a magnetic field to avoid in a very simple and elegant way the non-specific adsorption. Immunological reaction is performed under a competitive enzyme-linked immunosorbent assay (ELISA) where the mycotoxin ZEA and an enzyme-labelled derivative compete for the binding sites of the specific monoclonal antibody immobilised onto protein G modified magnetic beads. Horseradish peroxidase (HRP), in the presence of hydrogen peroxide, catalyses the oxidation of hydroquinone (HQ) to benzoquinone (BQN), whose back electrochemical reduction was detected at +0.1 V. Controlled-electrokinetic fluidic handling optimized conditions are addressed for all analytical steps cited above, and allows performing the complete immunoassay for the target ZEA analyte in less than 15 minutes with unique analytical merits: competitive immunoassay currents showed a very well-defined concentration dependence with a good precision as well as a suitable limit of detection of 0.4 µg L(-1), well below the legislative requirements, and an extremely low systematic error of 2% from the analysis of a maize certified reference material revealing additionally an excellent accuracy. Also, the reliability of the approach is demonstrated by the analysis of selected infant foods yielding the strictest ZEA permitted levels and excellent recoveries of 103 and 101% for solid and liquid samples, respectively.

Heterogeneous immunoassays in microfluidic format using fluorescence detection with integrated amorphous silicon photodiodes

Miniaturization of immunoassays through microfluidic technology has the potential to decrease the time and the quantity of reactants required for analysis, together with the potential of achieving multiplexing and portability. A lab-on-chip system incorporating a thin-film amorphous silicon (a-Si:H) photodiode microfabricated on a glass substrate with a thin-film amorphous silicon-carbon alloy directly deposited above the photodiode and acting as a fluorescence filter is integrated with a polydimethylsiloxane-based microfluidic network for the direct detection of antibody-antigen molecular recognition reactions using fluorescence. The model immunoassay used consists of primary antibody adsorption to the microchannel walls followed by its recognition by a secondary antibody labeled with a fluorescent quantum-dot tag. The conditions for the flow-through analysis in the microfluidic format were defined and the total assay time was 30 min. Specific molecular recognition was quantitatively detected. The measurements made with the a-Si:H photodiode are consistent with that obtained with a fluorescence microscope and both show a linear dependence on the antibody concentration in the nanomolar-micromolar range.